VytronUS, Inc.: Series B $11M

Posted in I - Series B, Q - 2Q09, R - WEST, X - Device (Cardiology), XX - CA

VytronUS (Sunnyvale, CA) a stealth, assumed early-stage cardiac medical device company focused on cardiology, closed an $11M Series B financing. Participants include Delphi Ventures and New Enterprise Associates.

Gyros, AB: Series C* $10.4M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Device (Protein Assay)

Gyros (Sweden) a commercial-stage provider of platform-based tools for therapeutic protein assay optimization, closed a $10.4M Series C* financing. Participants include SLS Invest and Industrifonden.

*Investment round undisclosed

Savara Pharmaceuticals, Inc.: Series A $1.0M

Posted in I - Series A, Q - 2Q09, R - SOUTH WEST, X - Device (Delivery), XX - TX

Savara Pharmaceuticals (Austin, TX) a preclinical-stage developer of dry powder and nebulized-based therapeutic inhalation drug delivery platform, closed a $1.0M Series A financing. Participants were not identified.

Embrella Cardiovascular, Inc.: Series B $5.1M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - Device (Cardiology), XX - PA

Embrella Cardiovascular (Malvern, PA) an early-stage medical device company focused on cerebral embolic protection during cardiovascular procedures, closed a $5.1M Series B financing. Participants include BioStarVentures, Edwards Lifesciences and MedFocus Fund.

Capella, Inc.: Series C $17.3M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Device (Cardiology), X - Device (Stent), X - Device (Vascular)

Capella (Ireland) a development-stage medical device company focused on stents for bifurcation vascular disease complex coronary artery disease, cloased a $17.3M Series C financing. Participants include Fountain Healthcare Partners, Mitsui & Co., Enterprise Ireland, Polytechnos Partners and ACT Venture Capital.

Solazyme, Inc.: Series C $57M

Posted in I - Series C, Q - 2Q09, R - WEST, X - Biofuel, XX - CA

Solazyme (San Francisco, CA) a development-stage biofuels company focused on the bioproduction of microalgae molecules for the energy, chemical, and nutraceutical industries, closed a $57M Series C financing. Participants include Braemar Energy Ventures, Lightspeed Venture Partners, VantagePoint Venture Partners, Roda Group and Harris & Harris Group.

NanoString Technologies, Inc.: Series C $30M

Posted in I - Series C, Q - 2Q09, R - NORTH WEST, X - Bioinformatics, XX - WA

NanoString Technologies (Seattle, WA) a commercial-stage developer of instrumentation and assays for multiplexed detection and quantification of gene expression, closed a $30M Series C financing. Participants include Clarus Ventures, OVP Venture Partners and Draper Fisher Jurvetson.

Inspire Medical Systems, Inc.: Series B $17M

Posted in I - Series B, Q - 2Q09, R - MID WEST, XX - MN

Inspire Medical Systems (Minneapolis, MN) an early-stage medical device company developing an implantable therapeutic device for the treatment of obstructive sleep apnea, closed a $17M Series B financing. Participants include Kleiner Perkins Caufield & Byers, Medtronic and U.S. Venture Partners.

Spiracur, Inc.: Series B $20.3M

Posted in I - Series B, Q - 2Q09, R - WEST, X - Device (Wound Healing), X - Wound Healing, XX - CA

Spiracur (Redwood City, CA) and early-stage medical device company focused on wound healing, closed a $20.3M Series B financing. Participants include Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures.